Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gabitril Seizure Warning Addresses Off-Label Use Of High Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston

You may also be interested in...



Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year

Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.

Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year

Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.

Cephalon’s Gabitril Marketing Scaled Back Pending Anxiety Trial Results

Sales of Gabitril declined 36% to $15.7 mil. in the second quarter.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel